捷榮(02119.HK)主席售21%股權 引入中信(00267.HK)旗下大昌行
捷榮國際(02119.HK)公布,由董事會主席、公司執行董事兼行政總裁黃達堂直接全資擁有的Hero Asia,於今日(19日)向大昌行出售公司合共1.51億股股份,相當於公司股本約21%,總代價為1.33億元。
公司指出,大昌行的中間控股公司為中國中信(00267.HK),通過出售事項引入大昌行作為戰略投資者,相信可利用大昌行集團的競爭優勢,廣泛的業務網路及扎實的專業知識,加強及擴大集團在中國的業務基礎,從而提高集團的整體收入及盈利能力。集團亦將與大昌行探索進一步潛在戰略合作,包括但不限於成立合資企業的可能性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.